Table 2.
IgG and IgA serological status of MGUS and myeloma patients with monoclonal IgA, as determined with the multiplexed infectious antigen micro-array (MIAA) assay.
| Pathogens | MGUS | Myeloma | MGUS and Myeloma | |||
|---|---|---|---|---|---|---|
| (n = 6) | (n = 26) | (n = 32) | ||||
| Negative | Positive | Negative | Positive | Negative | Positive | |
| IgG serology | ||||||
| EBV, n (%) | 0 | 6 (100%) | 0 | 26 (100%) | 0 | 32 (100%) |
| HCV, n (%) | 6 | 0 (0.0%) | 25 | 1 (3.1%) | 31 | 1 (3.1%) |
| CMV, n (%) | 4 | 2 (33.3%) | 12 | 14 (53.8%) | 16 | 16 (50.0%) |
| HSV-1, n (%) | 1 | 5 (83.3%) | 7 | 19 (73.1%) | 8 | 24 (75.0%) |
| HSV-2, n (%) | 3 | 3 (50.0%) | 15 | 11 (42.3%) | 18 | 14 (43.8%) |
| VZV, n (%) | 5 | 1 (16.7%)* | 22 | 4 (15.4%)* | 27 | 5 (15.6%)* |
| H. pylori, n (%) | 4 | 2 (33.3%) | 19 | 7 (26.9%) | 23 | 9 (28.1%) |
| T. gondii, n (%) | 5 | 1 (16.7%) | 17 | 9 (34.6%) | 22 | 10 (31.2%) |
| B. burgdorferi, n (%) | 5 | 1 (16.7%) | 26 | 0 (0.0%) | 31 | 1 (3.1%) |
| IgA serology | ||||||
| EBV, n (%) | 2 | 4 (66.7%) | 13 | 13 (50.0%) | 15 | 17 (53.1%)a |
| HCV, n (%) | 6 | 0 (0.0%) | 25 | 1 (3.8%) | 31 | 1 (3.1%) |
| CMV, n (%) | 5 | 1 (16.7%) | 26 | 0 (0.0%) | 31 | 1 (3.1%)b |
| HSV-1, n (%) | 4 | 2 (33.3%) | 24 | 2 (7.7%) | 28 | 4 (12.5%)c |
| HSV-2, n (%) | 5 | 1 (16.7%) | 22 | 4 (15.4%) | 27 | 5 (15.6%)d |
| VZV, n (%) | 4 | 2 (33.3%) | 14 | 12 (46.2%) | 18 | 14 (43.8%)e |
| H. pylori, n (%) | 5 | 1 (16.7%) | 18 | 8 (30.8%) | 23 | 9 (28.1%) |
| T. gondii, n (%) | 5 | 1 (16.7%) | 23 | 3 (11.5%) | 28 | 4 (12.5%)f |
| B. burgdorferi, n (%) | 5 | 1 (16.7%) | 21 | 5 (19.2%) | 26 | 6 (18.8%) |
Prior to the analysis of the specificity of purified monoclonal IgAs, the IgG serology status and the IgA serology status were assessed in parallel for 32 patients (6 MGUS, 26 myeloma) by analyzing serum samples (containing unseparated IgGs, unseparated IgAs, and monoclonal IgA) with the MIAA assay, revealed with either a DylightTM 680-labeled goat anti-human IgG Fc antibody or a DylightTM 680-labeled goat anti-human IgA Fc antibody.
Underestimated by the MIAA assay, the percentage of positive IgG serology for VZV in the general population being >90%.
p < 0.00001.
p < 0.00001.
p < 0.00001.
p = 0.0272.
p = 0.0272.
p = 0.1289 compared to the IgG serology, Fisher exact test.
EBV, Epstein–Barr virus; HCV, hepatitis C virus; CMV, cytomegalovirus; HSV, herpes simplex virus 1; VZV, varicella zoster virus; H. pylori, Helicobacter pylori; T. gondii, Toxoplasma gondii; B. burgdorferi, Borrelia burgdorferi.